9Y4.F 11.22 (-6.5%)
PLSELVT00013• Biotechnology• Biotechnology
Intro Numbers Peers
  1. Home
  2. /
  3. All Stocks
  4. /
  5. 9Y4.F

Ryvu Therapeutics (9Y4.F) Stock Highlights

11.22 | -6.5%
2024-10-21 04:18:54
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology.

Statistics

Range Today
11.22 11.22
Volume Today 0
Range 1 Year
10.94 15.4
Volume 1 Year 308
Range 3 Year
4.88 15.4
Volume 3 Year 6.04K
Range 10 Year
4.88 15.4
Volume 10 Year 6.59K

Highlights

Market Capitalization 281.01M (small)
Floating Shares 15.7M
Current Price 11.22
Price To Earnings -11.45
Price To Revenue 0.8
Price To Book 1.26
Earnings Per Share -0.98
Payout Ratio 0%

Performance

Latest -6.5%
1 Month -10.53%
3 Months +0.54%
6 Months -6.66%
1 Year -25.2%
3 Years -7.73%
5 Years +1.08%
10 Years +1.08%

Benchmarks

Market Capitalization

0 / 368

Gross Profits

0 / 278

Total Revenue

0 / 300

Total Rank

0 / 368

Free Cashflow

0 / 352

Performance 5 years

0 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.